{"organizations": [], "uuid": "40996d08d6bbdd073b1060df848199c504afa62d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/02/22/reuters-america-update-2-sangamo-in-3-billion-gene-editing-deal-with-gilead.html", "country": "US", "domain_rank": 767, "title": "UPDATE 2-Sangamo in $3 billion gene-editing deal with Gilead", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T17:21:00.000+02:00", "replies_count": 0, "uuid": "40996d08d6bbdd073b1060df848199c504afa62d"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/02/22/reuters-america-update-2-sangamo-in-3-billion-gene-editing-deal-with-gilead.html", "ord_in_thread": 0, "title": "UPDATE 2-Sangamo in $3 billion gene-editing deal with Gilead", "locations": [], "entities": {"persons": [{"name": "luxturna", "sentiment": "none"}, {"name": "sandy macrae", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "california", "sentiment": "none"}], "organizations": [{"name": "gilead", "sentiment": "negative"}, {"name": "sangamo", "sentiment": "negative"}, {"name": "reuters", "sentiment": "none"}, {"name": "gilead sciences inc", "sentiment": "none"}, {"name": "sangamo therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "* Gilead to pay Sangamo $150 mln upfront\n* Sangamo gene-editing tech to be used for cancer therapies\n* Sangamo stock jumps 21 percent (Adds CEO and executive quotes, background, updates share price)\nFeb 22 (Reuters) - U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.\nThe deal is the latest by a major drugmaker looking to develop lucrative gene therapies that have the potential to treat ailments by directly targeting disease-causing genes.\nShares of California biotech firm Sangamo jumped more than 20 percent to a 17-year high of $27.30 on Thursday morning.\n\"These are indeed exciting times in the field of genome-editing and gene therapy,\" Sangamo Chief Executive Officer Sandy Macrae said on a call with analysts.\nIn December, Luxturna, a treatment for a rare disease that causes blindness, became the first gene therapy for an inherited disease to get U.S. regulatory approval.\nThe treatment, developed by Philadelphia-based Spark Therapeutics Inc, is expected to be priced at $850,000.\nGilead subsidiary Kite Pharma will use Sangamo's platform to target a class of proteins called zinc finger nucleases in order to edit the human genome, helping develop therapies for cancer.\nSangamo will receive $150 million upfront and is eligible for up to $3.01 billion in future payments tied to regulatory and other milestones.\nGilead snapped up Kite Pharma in a $12 billion deal last year as a way to get access to an emerging class of cancer immunotherapies called CAR-T and to offset slowing sales of its hepatitis C medicines.\nOther firms specializing in CAR-T such as Juno Therapeutics have signed deals to use another kind of gene-editing technology called CRISPR.\nGilead said earlier this month it would pursue collaborations with companies for gene-editing technology.\n\"(Gilead) scoured the field,\" said Curt Herberts, Sangamo's chief business officer.\nCompanies with gene-editing platforms including Editas Medicine and CRISPR Therapeutics saw their shares jump after Gilead signaled interest in the technology. (Reporting by Manas Mishra in Bengaluru; Editing by Savio D'Souza and Sai Sachin Ravikumar)", "external_links": [], "published": "2018-02-22T17:21:00.000+02:00", "crawled": "2018-02-23T01:05:35.016+02:00", "highlightTitle": ""}